Pharmacogenomic Testing for Geriatric Patients

Pharmacogenomic testing for geriatric patients can help explain why an older adult reacts strongly to one medicine or gets little benefit from another. Below, we look at why it matters with age, then add practical guidance on common drug-gene pairs, polypharmacy, Medicare and how caregivers can use the results.

As the world’s population age, problems like managing complex medical needs in older patients often present themselves to doctors. Polypharmacy is common in geriatric care. It usually means taking five or more medications at the same time, often because chronic diseases like hypertension, diabetes, and arthritis occur more frequently with age. This, however, exposes patients to ADRs, drug-drug interactions, and therapeutic failures.

One of the most promising solutions in recent times is the PGx Gene test of RPh Labs. It analyzes an individual’s genetic makeup to understand how a patient might react to a particular course of medication. In a geriatric patient, pharmacogenetic testing allows for the utilization of drug therapies to minimize adverse effects and optimize the outcome of treatment.

This blog post attempts to balance the advantages of Pharmacogenomic testing for geriatric patients against the challenges. It discusses how advanced personalized medicine can be in improving the quality of care.

What is Pharmacogenomics?

Pharmacogenomics is the science of understanding how an individual’s genetic makeup decides his drug response. While traditional pharmacology deals with how drugs interact inside the body, pharmacogenomics concerns how different variations of an individual’s genetics may alter certain medications’ absorption, distribution, metabolism, and excretion. It also considers how genetics could modify the interaction of a drug with its target in the body.

These caused by variations in genetics can affect several processes, including:

• Drug Absorption: The degree to which a drug becomes available in the bloodstream.
• Drug Metabolism: Rate and extent to which the body metabolizes and clears out the drug.
• Drug Efficacy: The effectiveness of the drug for an individual.
• Risk of side effects: Genetic variation can make a patient more sensitive or less responsive to the adverse impacts.

Armed with such genetic information, the PGx Gene test equips healthcare providers with the appropriate medication use likely to have the desired therapeutic benefit at the lowest risk of adverse effects.

Why is PGx Genetic Testing Important for Geriatric Patients?

Aging is disposed to many physiological changes in the body affecting the metabolism of drugs. One aspect makes geriatric patients more vulnerable to adverse effects that are:

• Decreased renal and hepatic function: Age is associated with reduced activities of the kidneys and liver, which affect the metabolism and clearance of most medications. The result is an accumulation of drugs and, thus, an increased possibility of toxicity.
• Polypharmacy: Elderly patients generally receive multiple drugs for chronic diseases, increasing the risk of drug-drug interactions.
• Alterations in body composition: Muscle mass reduces while fat deposits gain with age. Since the biodistribution of the drug is altered, this can impact the medications administered to patients.
• Age-related changes in receptor sensitivity: The rate of response of receptors to the drug may be different among various sets of age groups in the brain and body, which further influences the drug profile and risk associated with that drug

Pharmacogenetic tests help overcome these barriers by handling the management of a drug using a more accurate approach.

Critical Benefits of PGx Test for Older Patients

Reduced Risk of Adverse Drug Reactions

ADRs are a major cause of illness, hospital visits and deaths among older adults. Some adverse reactions occur due to genetic variations that influence a drug’s metabolism or interaction with its receptor site. PGx tests can identify genetic variations predisposing patients to ADRs, enabling clinicians to choose safer medications or adjust dosages that may reduce risks.

Optimized Drug Selection

Due to genetic diversity, drugs often function less effectively or are more sensitive in elderly patients. PGx DNA testing is useful for clinicians as it enables doctors to select drugs that may potentially be better suited and have greater efficacy. For example, a drug of a particular selection might make no difference if administered to a patient who has specific gene variations, while another drug may be of use to such a patient.

Personalised Drug Dosing

Drug levels in the blood vary with age since aging affects metabolism. Pharmacogenetic testing can help guide the dose of some drugs based on a patient’s genetic profile, alongside age, kidney and liver function, potentially averting underdosing, which may lead to some drug failure, or overdosing, which may cause toxicity. This is particularly important for drugs with narrow therapeutic windows, such as warfarin, and for drugs where gene-based dosing guidance exists, such as some antidepressants and certain medications used for the management of pain.

Improved Patient Medication Adherence

Personalized medicine based on a patient’s genetic profile may lead to effective treatment outcomes. If patients tend to have lower side effects and advanced therapies, the likelihood of sticking to their treatment regimen increases. Enhanced medication adherence leads to better disease management and quality of life.

Avoidance of drug-drug interactions

>Many older patients are on a variety of medications, which increases the likelihood of adverse drug-drug interactions. PGx tests can identify genes involved in drug metabolism, which can help clinicians avoid prescribing drugs that might negatively interact with other medications a patient is on. This could reduce complications and improve the overall safety of a treatment program.

Long-Term Cost-Effectiveness

Although the genetic-based test has an upfront cost, some studies suggest it may help offset costs over time by preventing some adverse drug reactions, reducing hospital time caused by side effects, and tailoring medicine use. It may also reduce trial-and-error prescribing by helping identify suitable drugs and dosages earlier, although the savings vary from patient to patient.

Challenges in Executing PGx Testing for Older Patients

While it is evident that the benefits of PGx testing are worth all the fuss, there are numerous barriers to its acceptance, especially for geriatric patients.

Level of Awareness and Education

Many providers, including geriatricians, may need to be made aware of the full potential of PGx testing or know how to use their genetic results in practice. Education and training are necessary to enable the healthcare professional to interpret PGx testing results effectively and apply them in patient care.

Complexity of Genetic Data

Interpretation of genetic information may be complex, especially for multi-gene testing to determine multiple attributes of drug metabolism. The issue arises in knowing which variants have clinical significance and would help guide drug selection or dosing recommendations. Hopefully, this will become easier as more clinical decision-support tools and experts are developed.

Cost and Access to Testing

Even though PGx tests have become less costly with time, many patients, especially those without health insurance offering genetic testing coverage, find the cost deterring.

Ethical and Privacy Issues

Genetic testing is a very sensitive issue in the context of privacy and consent. Moreover, genetic discrimination could be another major issue. Patients can only gain trust in healthcare if they are fully aware of what PGx genetic testing holds for them and that their genetic data is safe.

Restricted Reimbursement

Although some insurance plans cover Pharmacogenetic tests, reimbursement is spotty, especially for older patients who may be eligible for Medicare or Medicaid. This is highly burdensome for some patients who can benefit from personalized medication management.

Geographical accessibility:

Pharmacogenomic testing might also be excluded due to healthcare settings. Testing, for instance, might not be readily available at rural or underprivileged locations.

Advancing Toward Personalized Care of Older Adults

Despite these challenges, pharmacogenomics in geriatric medicine is undoubtedly promising. Personalized care indeed signals a step toward more effective, safer, and patient-centered care approaches. PGx testing uses a powerful tool to tailor treatment plans to each patient’s genetic profile.

The research in pharmacogenomics will continue to expand, resulting in a greater number of databases, better clinical guidance, and PGx testing becoming more common in healthcare systems. Maybe one day, PGx testing for the elderly will become routine care and appropriate and effective treatment for older adults will find its way to most patients.

Common medicines in older adults that have gene guidance

Many of the medicines older adults take every day have published gene guidance from CPIC or gene information in their FDA labels. These are the places where pharmacogenomic testing for geriatric patients is most likely to change a decision.

• Clopidogrel (CYP2C19): poor metabolizers activate less of this blood thinner and may get less protection after a stent or stroke.
• Warfarin (CYP2C9 and VKORC1): variants can lower the dose needed and raise bleeding risk early in treatment.
• Simvastatin (SLCO1B1): decreased function raises the risk of muscle pain and damage. See our guide to SLCO1B1 decreased function.
• Codeine and tramadol (CYP2D6): both need CYP2D6 to become active, so results affect pain relief and safety.
• SSRIs and tricyclic antidepressants (CYP2C19 and CYP2D6): common for depression, anxiety and nerve pain.
• Proton pump inhibitors such as omeprazole (CYP2C19): widely used for reflux and stomach protection.

You can look up specific drugs on our medication list by gene, which covers 263 medications, or check the FDA’s table of pharmacogenetic associations.

Polypharmacy in elderly patients and drug-gene interactions

Polypharmacy in elderly patients is usually described as taking five or more medicines at once, although definitions vary. The more medicines involved in polypharmacy in elderly adults, the more chances there are for them to compete for the same enzymes.

Genes add another layer. Doctors call this a drug-drug-gene interaction. A person may be a normal CYP2D6 metabolizer on paper, but if they also take a strong CYP2D6 blocker such as paroxetine, fluoxetine or bupropion, the enzyme behaves as if it barely works. Metoprolol, a common heart drug processed largely by CYP2D6, can then build up and slow the heart more than expected.

Another well-known example involves clopidogrel. Omeprazole and esomeprazole can reduce how much clopidogrel is activated, and the FDA label advises avoiding that combination. For a CYP2C19 intermediate or poor metabolizer, the effect adds to an already reduced activation.

This is why polypharmacy in elderly adults is one of the strongest reasons to test. A gene report read together with the full medicine list, including over-the-counter products and supplements, gives prescribers a clearer view than either source alone. Our guide to CYP2D6 inhibitors explains this effect in more detail.

Adverse drug reactions in elderly adults: where genes fit

Adverse drug reactions in elderly adults often look like ordinary signs of aging. Confusion, dizziness, falls, constipation, low energy or poor appetite can all be caused by a medicine. That makes them easy to miss.

Many factors raise the risk of adverse drug reactions in elderly adults, including lower kidney function, liver changes, frailty, dehydration and the number of medicines taken. Genes are one more factor, and they matter most for drugs with a narrow safety margin. Examples include bleeding with warfarin, muscle pain with simvastatin, and too much sedation with some opioids or tricyclic antidepressants.

Warning signs worth reporting to a prescriber include:

• New confusion or memory changes after starting or raising a medicine
• Falls, unsteadiness or dizziness when standing
• Unusual bruising, bleeding gums or dark stools
• Muscle pain or weakness without a clear cause
• Heavy sleepiness, slowed breathing or a very slow pulse

Seek urgent care for severe symptoms, since some adverse drug reactions in elderly people can become serious quickly. For milder ones, a gene report can help the prescriber understand whether a reaction is linked to how a drug is processed, or to something else entirely.

The Beers Criteria and PGx results together

The American Geriatrics Society Beers Criteria is a widely used list of medicines that may be inappropriate or need extra care in adults 65 and older. It flags drugs such as strongly anticholinergic medicines, some sleep aids and long-acting benzodiazepines, largely because of risks like confusion, falls and other adverse drug reactions in elderly adults.

The Beers Criteria and pharmacogenomics answer different questions. Beers asks whether a drug is risky for older adults in general. A gene report asks how this particular person is likely to process it. Used together, they give a fuller picture.

Amitriptyline is a good example. It appears on the Beers Criteria because of strong anticholinergic effects, and it is also processed by CYP2D6 and CYP2C19. For an older adult who is a poor metabolizer, higher drug levels could make those side effects even more likely. A prescriber might then lean toward a different option or a lower dose.

Many pharmacists and geriatric clinicians already use the Beers Criteria in medication reviews. Adding gene results to that review is a practical way to make pharmacogenomic testing for geriatric patients part of routine care.

How to request pharmacogenomic testing for geriatric patients

Families and caregivers often start the conversation about pharmacogenomic testing for geriatric patients. Here is a simple way to move from interest to results:

1. Make a complete list of medicines, doses and supplements, or bring all bottles to the next appointment.
2. Note any past reactions, such as bleeding, muscle pain, confusion or a medicine that never seemed to work.
3. Ask the primary care doctor, geriatrician or pharmacist whether gene testing could help with current or planned medicines.
4. Order a test. The RPh Labs at-home PGx kit uses a painless cheek swab that a caregiver can help collect.
5. Share the report with every prescriber and the pharmacy, and ask for it to be added to the medical record.

Results arrive 7 to 10 business days after the sample reaches our CLIA-certified, COLA-accredited lab in Dallas, Texas. Every report is reviewed by a PharmD pharmacist, and a free pharmacist consultation is included. Providers can find ordering details on our provider page.

Medicare and PGx testing for seniors

Cost is a common concern with PGx testing for seniors. Medicare may cover pharmacogenomic testing when it is medically necessary and ordered for a specific treatment decision. Coverage rules depend on the test, the medicine involved and local Medicare policies.

Medicare’s national coverage determination 90.1 addresses gene testing for warfarin response specifically. You can read it on the CMS website. For other uses, coverage is decided under separate policies, and our guide does Medicare cover pharmacogenomic testing explains the details.

RPh Labs accepts Medicare, as well as Texas Medicaid (TMHP) and Blue Cross Blue Shield of Texas. When Medicare may not pay, you may be asked to sign an Advance Beneficiary Notice, and our insurance billing and Medicare ABN forms are available on the forms page.

If you prefer to self-pay, the price is $299. It is HSA and FSA eligible and can be split into 4 interest-free installments. Questions about PGx testing for seniors can go to our team at (888) 383-2181.

When kidney and liver changes affect the results

Genes do not change with age, so results from pharmacogenomic testing for geriatric patients stay valid for life. What changes is the rest of the body. That is why a report should be read again whenever health or medicines change.

• Kidney function: many drugs are cleared by the kidneys, and gene results do not account for this. Doses may need lowering as kidney function declines.
• Liver disease: can reduce enzyme activity regardless of genotype.
• Serious illness or inflammation: can temporarily slow some drug-processing enzymes.
• New medicines: can block or boost enzymes and change how the report applies.

For these reasons, pharmacogenomic testing for geriatric patients is one input among many. Age, kidney and liver function, weight, other conditions and every other medicine still shape the final choice. No medicine should be stopped or changed without talking to the prescriber first.

RPh Labs updates reports when guidelines change, so the same results can support decisions years later.

Caregiver checklist for PGx testing for seniors

Caregivers often manage appointments, pharmacies and pill organizers. This short checklist helps make PGx testing for seniors useful instead of just another piece of paper.

• Keep a printed copy of the report with the medicine list and bring both to every visit.
• Give a copy to each specialist, the primary care office and the regular pharmacy.
• Ask about the report whenever a new medicine is started, especially after a hospital stay, when polypharmacy in elderly patients often increases.
• Watch for new confusion, falls or bleeding after any medicine change and report them promptly.
• Schedule a yearly medication review that covers both the gene report and the Beers Criteria.
• Keep the report where other family members can find it in an emergency.

The MedlinePlus overview of pharmacogenomics is a helpful plain-language resource if other family members want to understand the basics.

Conclusion

Pharmacogenomic testing is the cutting edge for medicating geriatric patients. Personalized drug selection and dosing based on unique genetic profiles may lead healthcare providers to better outcomes, fewer adverse medication effects, and an enhanced quality of life for older adults. As personalized medicine increasingly becomes part of the clinical practice arsenal, PGx testing will become crucial in helping keep care safe, effective, and individualized in aging populations.

References

Incitehealth

Pharmacogenomic testing for geriatric patients FAQ

Is there an age limit for a PGx test?

No. Inherited genes do not change with age, so adults can be tested at any point. For older adults, testing is often most useful when several medicines are involved or when a new treatment such as clopidogrel, warfarin, a statin or an antidepressant is planned.

Can a gene test reduce adverse drug reactions in elderly patients?

It can help with reactions that are linked to how a drug is processed, such as bleeding on warfarin or muscle pain on simvastatin. Many reactions have other causes, such as kidney function or drug interactions, so the report works best as part of a full medication review.

How does polypharmacy in elderly adults affect test results?

The genes themselves do not change, but other medicines can block or boost the same enzymes. A person can act like a poor metabolizer while taking a strong inhibitor. That is why prescribers read the report alongside the complete medicine list.

Does the Beers Criteria replace gene testing?

No. The Beers Criteria lists medicines that may be risky for older adults in general. A gene report shows how one person is likely to process specific drugs. Clinicians often use both together during a medication review.

Can a caregiver collect the sample?

Yes. The RPh Labs kit uses a painless cheek swab, and a caregiver can help collect it at home by following the instructions. The sample is mailed back in the prepaid mailer, with free shipping both ways.